Combined therapy with probiotic VSL#3 and Omega-3 fatty acids attenuates colonic injury and inflammation in chronic DNBS-induced colitis in mice (vol 69, pg 135, 2021)
Göster/ Aç
Erişim
info:eu-repo/semantics/openAccessTarih
2022Yazar
Yoldaş İlktaç, HavvanurKızıltan, Gül
Devrim Lanpir, Aslı
Ozansoy, Mehmet
Günal, Mehmet Yalçın
Özmen Toğay, Sine
Keskin, İlknur
Özdemir, Ekrem Musa
Kılıç, Ülkan
Üst veri
Tüm öğe kaydını gösterKünye
Yoldaş İlktaç, H., Kızıltan, G., Devrim Lanpir, A., Ozansoy, M., Günal, M. Y., Özmen Toğay, S. ... Kılıç, Ü. (2022). Combined therapy with probiotic VSL#3 and Omega-3 fatty acids attenuates colonic injury and inflammation in chronic DNBS-induced colitis in mice (vol 69, pg 135, 2021). Folia Biologica-Krakow, 70(1), 43-43. https://doi.org/10.3409/fb_70-1.05Özet
We published the abovementioned article about probiotic mixture VSL#3 on October 6, 2021. Since the product was named VSL#3 in our purchasing process in early 2016, it is referred to as VSL#3 in our article. In addition, the product currently known as VSL#3 is not the same as De Simone Formulation. De Simone Formulation is now available as Visbiome® in the United States and Vivomixx® in Europe. The authors would like to apologise for any inconvenience caused.